Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-014 adjuvant V940 (intismeran autogene) ± MK-3475A in high-risk stage I NSCLC
2025-522643-18-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of intismeran autogene in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Planned start Jun 2026; status: authorised.
02
Drugs
intismeran autogene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522643-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522643-18-00.